Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of BR2021 vs BR2021-1 in Metastatic Pancreatic Adenocarcinoma
NCT06867497Phase 1Recruiting
- Sponsor
- Boryung
- Start
- Feb 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BR2021 in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Curve from time 0 to time t and Maximum Plasma Concentration. Started Feb 2025; status: recruiting.
02
Drugs
BR2021
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06867497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06867497.